Menu

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

Nov 9, 2018
Biosearch Technologies

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

Biosearch Technologies will focus on further developing its capabilities in NGS and Nucleic Acid Chemistry, which build on expertise in existing genomic analysis applications such as genotyping, PCR and qPCR it promotes to Agrigenomics and Human Healthcare customers.

Brian Kim, President and Managing Director, Biosearch Technologies, said: “We believe the time is ripe to introduce a new unifying name that conveys our differentiated position in the market place.”

“We’ve seen considerable expansion and are reaching customers in more places around the world than ever before. As LGC, Biosearch Technologies continues to grow, it is important that we tell our collective story in a united and cohesive way.”

Biosearch Technologies will streamline products from across legacy brands to ensure that the tools work together for customer needs.   The name “Biosearch Technologies” reflects the innovation and progressiveness of the brand and embodies a forward-looking and continuously developing offer from LGC.

In recent years, LGC’s Genomics division has seen rapid expansion through a series of targeted and strategic acquisitions.   This approach has introduced a number of new products that support mission critical customer applications.   Biosearch Technologies integrates these genomic analysis tools combining expertise in manufacturing and design of enzymes and oligonucleotides, instrumentation engineering, extraction chemistries, and reagent and consumable development under one brand to deliver innovation to the life science market

Mark Dearden, Vice President of Strategy and Marketing, Biosearch Technologies, said: “Every day through capabilities in enzyme engineering, genotyping technologies or custom oligos, we support mission critical customer applications.  We state mission critical because if we don’t deliver to our customers, it might mean that they cannot manufacture a kit for an infectious disease diagnostic or that they cannot deliver the data sets that reduce the time to complete plant breeding decisions. We are bringing our collective knowledge and expertise to propel us and our customers forward.”

LGC, Biosearch Technologies leverages applied genomics to accelerate mission critical customer applications.  We strive to harness the power of the genomic tools and technologies, and through close collaboration, we enable our customers to achieve more.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.
Corning Introduces New 1536-well Spheroid Microplate
Corning Introduces New 1536-well Spheroid Microplate
High-throughput spheroid microplate benefits cancer research, drug screening